NOVARTIS
KISQALI (ribociclib)
Novartis presented the updated study results of the MONALEESA-3 trial. Kisqali plus fulvestrant showed a significant overall survival (OS) of more than five and half years when given as first-line therapy in postmenopausal women living with HR+/HER2 breast cancer.
Kisqali plus fulvestrant increased the survival benefit by sixteen months compared to fulvestrant alone when given as first-line therapy. Further, Kisqali is the only CDK4/6 inhibitor-fulvestrant combination that demonstrated overall survival when administered as first-line therapy. Additionally, Novartis announced that among the CDK4/6 inhibitors, Kisqali had demonstrated the longest overall survival irrespective of combination partner, line of treatment, menopausal status, or site, and the number of metastases.
Novartis presented the updated data of MONALEESA-3; after a median follow-up of five years in the first-line setting, Kisqali plus fulvestrant combination showed an overall survival of 67.6 months compared to 51.8 months in patients who were administered with fulvestrant alone.
PFIZER
IBRANCE
Pfizer presented the real-world evidence data of Ibrance (palbociclib) in combination with an aromatase inhibitor (AI) in patients with HR+/HER2-metastatic breast cancer (mBC).
The median progression-free survival was 49.1 months in Ibrance + aromatase inhibitor group compared to 43.2 months in the aromatase inhibitor group. The median progression-free survival was 19.3 months versus 13.9 months in patients on an aromatase inhibitor.
Komentarze